Abstract: Objectives To assess the efficacy of drug therapy on hepatitis B virus associated glomerulonephritis (HBV-GN) by a systematic review and meta-analysis of clinical trials. Methods Electronic databases including Pubmed, Cochrane library, EMBASE, MEDLINE, CBM, CNKI and VIP were searched for prospective controlled trials which assessed the efficacy of drug therapy on HBV-GN in adult or pediatric patients from Jan. 1980 to July. 2012. Study selection and meta-analysis were conducted according to the Cochrane handbook for systematic reviews. Data were extracted from these trials by three reviewers independently and analyzed by Revman 5.0 and stata 10.0 software. Results Nine trials with a total of 331 patients were included; among them, six trials were specified as the anti-viral therapy group, three studies were about interferon, two about lamividine and one about entecavir. It was found by the meta-analysis that, compared with the controls, anti-viral therapy could significantly elevate the remission rate of proteinuria (RR = 1.37, 95%CI 1.16-1.60, P = 0.0001) and the clearance rate of HBeAg (RR = 3.28, 95%CI 2.18-4.94, P ＜ 0.00001). Futhermore, Kappa analysis showed positive correlation between proteinuria remission and HBeAg clearance after anti-viral therapy (Kappa = 0.352, P = 0.003). Another three trials were specified as the combined therapy (antivirals and immunosuppressants) group. Meta-analysis showed there was no significant difference between the combined treatment group and the controls in the remission rate of proteinuria (RR = 2.34, 95%CI 1.31, 4.16, P = 0.04) and the clearance rate of HBeAg (RR = 0.98, 95%CI 0.30-3.25, P = 0.97). Conclusions This study showed the antiviral therapy (including interferon , lamivudine, entecavir) in HBV-GN is effective on remission of proteinuria and HBeAg clearance, the combined treatment could not conduct such effort in this study. For further research on combined treatment, more trials should be performed in the clinical.